相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Shekoufeh Nikfar et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2016)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543
Kazuhiro Ikegai et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Design and Synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as Dipeptidyl PeptidaseIV Inhibitors
Linrong Zhu et al.
CHEMMEDCHEM (2013)
Advances in Pharmacologic Therapies for Type 2 Diabetes
Linde M. Morsink et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Sirtuins as Possible Drug Targets in Type 2 Diabetes
Munehiro Kitada et al.
CURRENT DRUG TARGETS (2013)
Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus
E. Panzhinskiy et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Connective tissue growth factor, matrix regulation, and diabetic kidney disease
Susan V. McLennan et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2013)
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Y. Saisho et al.
DIABETIC MEDICINE (2013)
Canagliflozin: First Global Approval
Shelley Elkinson et al.
DRUGS (2013)
Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
Andre Scheen
EXPERT OPINION ON DRUG SAFETY (2013)
Effect of Chromium on Glucose and Lipid Profiles in Patients with Type 2 Diabetes; A Meta-analysis Review of Randomized Trials
Amir Farshchi et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2013)
Structure of the human glucagon class B G-protein-coupled receptor
Fai Yiu Siu et al.
NATURE (2013)
Glucose Levels and Risk of Dementia
Paul K. Crane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Eiji Kurosaki et al.
PHARMACOLOGY & THERAPEUTICS (2013)
CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
V. K. Vyas et al.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH (2013)
Reprogramming of Intestinal Glucose Metabolism and Glycemic Control in Rats After Gastric Bypass
Nima Saeidi et al.
SCIENCE (2013)
Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives
Sara Mostafalou et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Shinji Furuta et al.
XENOBIOTICA (2013)
Pancreatitis: A Potential Complication of Liraglutide?
Andrea S. Franks et al.
ANNALS OF PHARMACOTHERAPY (2012)
Stimulation of Hepatic Glycogenolysis and Inhibition of Gluconeogenesis are the Mechanisms of Antidiabetic Effect of Centaurea bruguierana ssp belangerana
Mahnaz Khanavi et al.
ASIAN JOURNAL OF ANIMAL AND VETERINARY ADVANCES (2012)
Multi-organ Protective Effects of Cerium Oxide Nanoparticle/Selenium in Diabetic Rats: Evidence for More Efficiency of Nanocerium in Comparison to Metal Form of Cerium
Mona Navaei-Nigjeh et al.
ASIAN JOURNAL OF ANIMAL AND VETERINARY ADVANCES (2012)
Fused bicyclic heteroarylpiperazine- substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors
Yohei Ikuma et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
Masakazu Imamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors
Dipam Patel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors
Chun-Hsu Yao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
It is Time to Formulate an Antioxidant Mixture for Management of Diabetes and its Complications: Notice for Pharmaceutical Industries
Asieh Hosseini et al.
INTERNATIONAL JOURNAL OF PHARMACOLOGY (2012)
SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Raktim Kumar Ghosh et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
SGLT2 inhibitors race to enter type-2 diabetes market
Cormac Sheridan
NATURE BIOTECHNOLOGY (2012)
Targeting the glucagon receptor family for diabetes and obesity therapy
Young Min Cho et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
Zeng-Hao Chen et al.
TETRAHEDRON LETTERS (2012)
Effect of chicory seed extract on glucose tolerance test (GTT) and metabolic profile in early and late stage diabetic rats
Abdolreza Ghamarian et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Recent Update on Animal and Human Evidences of Promising Anti-diabetic Medicinal Plants: A Mini-review of Targeting New Drugs
Shirin Hasani Ranjbar et al.
ASIAN JOURNAL OF ANIMAL AND VETERINARY ADVANCES (2011)
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554
Hironobu Maezaki et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
Noriyasu Kato et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl] cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors
Ping Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-γ/δ dual agonists
Hyo Jin Gim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Synthesis and antigastric ulcer activity of novel 5-isoproyl-3,8-dimethylazulene derivatives
Lu-Yun Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Synthesis of variously coupled conjugates of D-glucose, 1,3,4-oxadiazole, and 1,2,3-triazole for inhibition of glycogen phosphorylase
Sandor Kun et al.
CARBOHYDRATE RESEARCH (2011)
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
Alan J. Garber
DIABETES CARE (2011)
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Kasia J. Lipska et al.
DIABETES CARE (2011)
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
Baptist Gallwitz
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Software and resources for computational medicinal chemistry
Chenzhong Liao et al.
FUTURE MEDICINAL CHEMISTRY (2011)
No Superiority of Exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis
Pooneh Salari et al.
INTERNATIONAL JOURNAL OF PHARMACOLOGY (2011)
Discovery of Novel N-β-D-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes
Chun-Hsu Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors
Vincent Mascitti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Review of the Potential Benefits of Pentoxifylline in Diabetic and Non-Diabetic Proteinuria
Shirinsadat Badri et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2011)
SGLT2 inhibitors: molecuar design and potential differences in effect
Masayuki Isaji
KIDNEY INTERNATIONAL (2011)
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
Timothy Colin Hardman et al.
Diabetes Therapy (2011)
Role of β-Adrenergic Receptor Regulation of TNF-α and Insulin Signaling in Retinal Muller Cells
Robert J. Walker et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
Tang Peng Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
Robert P. Brigance et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors
Chih-Hung Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Thiadiazole-based Thioglycosides as Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors
Gao Yunlong et al.
CHINESE JOURNAL OF CHEMISTRY (2010)
The Genetics of Insulin Resistance: Where's Waldo?
Richard M. Watanabe
CURRENT DIABETES REPORTS (2010)
Declining β-Cell Compensation for Insulin Resistance in Hispanic Women With Recent Gestational Diabetes Mellitus - Association with changes in weight, adiponectin, and C-reactive protein
Anny H. Xiang et al.
DIABETES CARE (2010)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
DRUGS (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial
Sanaz Vosough-Ghanbari et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2010)
Discovery of Non-Glycoside Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Inhibitors by Ligand-Based Virtual Screening
Jian-Sung Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
Mary Parks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
GENOMIC MEDICINE Genomics, Type 2 Diabetes, and Obesity
Mark I. McCarthy
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oxidative stress and beta-cell dysfunction
Gisela Drews et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2010)
Effect of Phlomis persica on glucose levels and hepatic enzymatic antioxidants in streptozotocin-induced diabetic rats
Parisa Sarkhail et al.
PHARMACOGNOSY MAGAZINE (2010)
Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
Vincent Mascitti et al.
TETRAHEDRON LETTERS (2010)
Liraglutide in the management of type 2 diabetes
Estela Wajcberg et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2010)
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
Via
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy (2010)
Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
Yogendra Keche
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES (2010)
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Abd A. Tahrani et al.
ADVANCES IN THERAPY (2009)
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
Shrikanth H. Havale et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
Rajesh Gupta et al.
CURRENT DRUG TARGETS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
Renate E. van Genugten et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
The incretin system and its role in type 2 diabetes mellitus
Jens Juul Holst et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Islet transplantation and antioxidant management: A comprehensive review
Seyed Sajad Mohseni Salehi Monfared et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines
Ghazal Ansari et al.
ADVANCES IN THERAPY (2008)
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin - Glucose and lipid effects
Harold E. Bays et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones:: A class of potent DPP-4 inhibitors
Matthias Eckhardt et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of α-amylase
Peng Geng et al.
CARBOHYDRATE RESEARCH (2008)
New drugs for the treatment of diabetes - Part II: Incretin-based therapy and beyond
Silvio E. Inzucchi et al.
CIRCULATION (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Glucolipotoxicity:: Fuel excess and β-cell dysfunction
Vincent Poitout et al.
ENDOCRINE REVIEWS (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo
Yuka Someya et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
William J. Metzler et al.
PROTEIN SCIENCE (2008)
Diagnosis and classification of diabetes mellitus
DIABETES CARE (2008)
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Matthias Eckhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne et al.
NATURE (2007)
Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes
Ping Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond
G. Panina
DIABETES OBESITY & METABOLISM (2007)
Antidiabetic effect of Phlomis anisodonta:: Effects on hepatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes
Parisa Sarkhail et al.
PHARMACOLOGICAL RESEARCH (2007)
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors
Jason M. Cox et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients -: a randomized controlled double-blind and double-dummy multicentre clinical trial
J. Li et al.
DIABETES OBESITY & METABOLISM (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
4-Aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV
Joseph L. Duffy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
[(S)-γ-(4-Aryl-1-piperazinyl)-L-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors
Tomohiro Yoshida et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Lead optimization of [(S)-γ-(arylamino)prolyl]thiazolidine focused on γ-substituent:: Indoline compounds as potent DPP-IV inhibitors
Hiroshi Sakashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site
Christian Rummey et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
Kenji Katsuno et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity
Toshiyasu Sasaoka et al.
PHARMACOLOGY & THERAPEUTICS (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
A. Barnett
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Islet β cell failure in type 2 diabetes
Marc Prentki et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
[(S)-γ-(arylamino)proly]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors
Hiroshi Sakashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The place of sulfonylureas in the therapy for type 2 diabetes mellitus
S Del Prato et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Diabetes reduces basal retinal insulin receptor signaling - Reversal with systemic and local insulin
CEN Reiter et al.
DIABETES (2006)
Critical nodes in signalling pathways: insights into insulin action
CM Taniguchi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Pharmacophoric features of biguanide derivatives: An electronic and structural analysis
PV Bharatam et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans
S Cinti et al.
JOURNAL OF LIPID RESEARCH (2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus
IW Campbell
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2005)
The pharmacology of the insulinomimetic effect of zinc complexes
H Sakurai et al.
BIOMETALS (2005)
A review on the role of antioxidants in the management of diabetes and its complications
R Rahimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2005)
Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
DJ Augeri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial
M Radfar et al.
BIOMEDICINE & PHARMACOTHERAPY (2005)
Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients
F Astaneie et al.
ARCHIVES OF MEDICAL RESEARCH (2005)
Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors
SD Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Synthesis and insulin-mimetic activities of metal complexes with 3-hydroxypyridine-2-carboxylic acid
M Nakai et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2005)
Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors
JY Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats
E Milani et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY (2005)
Drug therapy: Insulin analogues
IB Hirsch
NEW ENGLAND JOURNAL OF MEDICINE (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Insulin secretagogues, sulfonylurea receptors and K-ATP channels
J Bryan et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Sulfonylurea treatment of type 2 diabetes mellitus: Focus on glimepiride
MT Korytkowski
PHARMACOTHERAPY (2004)
4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors
ER Parmee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Adipokines: inflammation and the pleiotropic role of white adipose tissue
P Trayhurn et al.
BRITISH JOURNAL OF NUTRITION (2004)
Repaglinide versus nateglinide monotherapy - A randomized multicenter study
J Rosenstock et al.
DIABETES CARE (2004)
Clinical pharmacokinetics of nateglinide - A rapidly-absorbed, short-acting insulinotropic agent
JF McLeod
CLINICAL PHARMACOKINETICS (2004)
Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability:: Interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors
DR Magnin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone
C Lagathu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva
M Abdollahi et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2003)
Possible heart failure exacerbation associated with rosiglitazone: Case report and literature review
RLP Page et al.
PHARMACOTHERAPY (2003)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apopiosis in human and rat hepatoma cell lines
MA Bae et al.
TOXICOLOGY LETTERS (2003)
Differential selectivity of insulin secretagogues - Mechanisms, clinical implications, and drug interactions
FM Gribble et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2003)
Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic β-cell-type KATP channels
M Chachin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Impairment of myocardial protection in type 2 diabetic patients
TM Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability
I Idris et al.
DIABETOLOGIA (2003)
Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy
SM Setter et al.
CLINICAL THERAPEUTICS (2003)
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
AJ Scheen
DRUGS (2003)
Insulin regulation of glucose uptake: A complex interplay of intracellular signalling pathways
AH Khan et al.
DIABETOLOGIA (2002)
Role of adiponectin in preventing vascular stenosis - The missing link of adipo-vascular axis
M Matsuda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
IRS proteins and the common path to diabetes
MF White
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Synthesis of new azulene derivatives and study of their effect on lipid peroxidation and lipoxygenase activity
E Rekka et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2002)
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats
JA Pospisilik et al.
DIABETES (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes
T Sasaoka et al.
DIABETOLOGIA (2001)
PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
N Maeda et al.
DIABETES (2001)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity
T Wada et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
LS Phillips et al.
DIABETES CARE (2001)
Mechanism by which metformin reduces glucose production in type 2 diabetes
RS Hundal et al.
DIABETES (2000)
Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin
R Perfetti et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2000)
Signaling pathways in insulin action: molecular targets of insulin resistance
JE Pessin et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
